Australia's most trusted
source of pharma news
Posted 13 October 2025 PM
US President Donald Trump has bagged his second price-cutting deal with a pharma company, announcing an agreement with British giant, AstraZeneca, resulting in "hundreds of millions of dollars" in savings.
Under the Most Favoured Nation (MFN) deal, AstraZeneca will provide every State Medicaid program in the US with drugs priced in line with the lowest paid by other developed nations. It is the second company to sign up to the deal, with Pfizer starting the ball rolling two weeks ago.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.